ALXO News and Press, ALX Oncology Holdings Inc. From 08/23/21

Trillium Therapeutics (NASDAQ:TRIL) +191% after acquisition by Pfizer for $2.3B Vivos Therapeutics (NASDAQ:VVOS) +61% on FDA 510k clearance for sleep apnea treatment device Xeris Pharmaceuticals (NASDAQ:XERS) +48% announces approval of supplemental new drug Application (sN...

ALX Oncology (NASDAQ:ALXO): Q2 GAAP EPS of -$0.40 beats by $0.06. Cash and Cash Equivalents: Cash and cash equivalents as of June 30, 2021, were $410.0 million.  Press Release For further details see: ALX Oncology EPS beats by $0.06

BURLINGAME, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the second quarter ended...

ALX Oncology Holdings (ALXO) in partnership with Merck (MRK) announce the first patient has been dosed in the Phase 2 ASPEN-04 study evaluating the combination of ALX148, a next generation CD47 blocker, with Keytruda (pembrolizumab), an anti-PD-1 therapy, and standard chemotherapy for the tre...

BURLINGAME, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, in partnership with Merck, known as MSD outside the United S...

janiecbros/E+ via Getty Images Biotech M&A is poised to heat up again as shares of the SPDR S&P Biotech’s (XBI) have fallen about 25% from their February highs, according to Jefferies. Biotech deals may pick up after a 3-6 month of a large "drawdown" and as prices "normalize" f...

peterschreiber.media/iStock via Getty Images ALX Oncology ([[ALXO]] +13.6%) has risen more than a tenth after announcing updated clinical data from its ongoing ASPEN-01 trial, which indicated more than 70% of objective response rate ((ORR)) for ALX148 as a combination therapy in gas...

-- ORR of 72% Observed in Patients with > 2L HER2 Positive Gastric or Gastroesophageal Junction Cancer -- Estimated OS at 12 months of 76% -- ALX Oncology to Host Conference Call on July 6 th at 8:30 a.m. ET BURLINGAME, Calif., July 03, 2021 (G...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead The earnings calendar is light next week as the first half of the year comes to a close, but Micron (NASDAQ:MU), General...

--Interim report completed by ALX for a standard ongoing non-clinical safety study --Based on the safety study results, the FDA has lifted a previously set partial clinical hold and cap on patient enrollment in ASPEN-03 and ASPEN-04 --The first of two distinct randomized...